Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 4/20 | 0.42 |
| ▸ | GSK3B | P49841 | 6/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.42 |
| ▸ | WNT1 | P04628 | 5/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.38 |
| ▸ | SCD | O00767 | 1/20 | 0.38 |
| ▸ | WDR5 | P61964 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17809502 | 0.94 | CREBBP (0.44) | CREBBPGSK3BDYRK1AWNT1USP30 | |
| SCHEMBL17809572 | 0.86 | CREBBP (0.50) | CREBBPBRD4 | |
| SCHEMBL19368731 | 0.84 | WNT1 (0.41) | CREBBPGSK3BDYRK1AWNT1USP30 | |
| SCHEMBL17806213 | 0.84 | CREBBP (0.41) | CREBBPGSK3BDYRK1AWNT1USP30 | |
| SCHEMBL17785617 | 0.82 | CYP11B2 (0.49) | CREBBPGSK3BDYRK1AWNT1USP30 | |
| SCHEMBL17794569 | 0.81 | USP30 (0.53) | CREBBPUSP30WDR5BRD4 | |
| SCHEMBL17809634 | 0.80 | CREBBP (0.57) | CREBBPBRD4 | |
| SCHEMBL22369071 | 0.79 | CREBBP (0.48) | CREBBPBRD4 | |
| SCHEMBL17806203 | 0.79 | CREBBP (0.44) | CREBBPGSK3BDYRK1AWNT1USP30 | |
| SCHEMBL17809646 | 0.78 | USP30 (0.58) | CREBBPUSP30WDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9763922-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | CREBBP 6/4885GSK3B 2555/4885DYRK1A 4494/4885 |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | CREBBP 6/4885GSK3B 2555/4885DYRK1A 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.